Navigation Links
Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa)
Date:4/26/2010

LAWRENCEVILLE, N.J., April 26 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN® (carbidopa) tablets from Bristol-Myers Squibb Company (BMS). LODOSYN is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of Parkinson's disease, to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother medication response.

"Levodopa itself is currently the most effective drug for relieving Parkinson's disease symptoms," explained George Plotkin, M.D., Ph.D., of the Movement Disorder Center in Tyler, TX, which treats more than 2,000 Parkinson's patients per year. "LODOSYN plays a key role in my Parkinson's patients for whom the dosage of levodopa is less than adequate. LODOSYN permits control of Parkinson's symptoms with much lower doses of levodopa and a resulting reduction in side effects."

"The acquisition of LODOSYN continues our mission to improve patient outcomes and quality of life by providing medically essential therapeutics, while enabling us to enter an important market," commented Michael G. Wells, Chief Executive Officer of Aton Pharma. "Nearly one million people in the U.S. are living with Parkinson's."

Parkinson's disease, a chronic, neurological illness that hampers movement and coordination, involves the destruction or impairment of dopamine-producing brain cells. Dopamine is a neurotransmitter, sending information to other parts of the brain to produce smooth movements. Levodopa and carbidopa are a combination of drugs that together, help to prevent Parkinson's symptoms. The drug combination works as a dopamine regulator, by increasing dopamine and assuring it stays within the brain. Carbidopa is given with levodopa to prevent it from being converted into dopamine outside the brain, helping prevent the side-effects of nausea and vomiting that occur when too much dopamine is outside of the brain. In addition, carbidopa decreases the amount of levodopa needed. Together, the two drugs provide an increase in dopamine in the brain, which is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.

LODOSYN is supplied by a 25 mg tablet in a bottle of 100 tablets. Aton Pharma, Inc. will now assume exclusive responsibility for its U.S. sales and distribution.

About LODOSYN

LODOSYN (carbidopa), an inhibitor of aromatic amino acid decarboxylation, is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism. LODOSYN is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa.

LODOSYN is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each entity. LODOSYN is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from the addition of carbidopa.

Although the administration of LODOSYN permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa.

Certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa.

LODOSYN has no anti-Parkinson's effect when administered alone. LODOSYN does not decrease adverse reactions due to central effects of levodopa.

When LODOSYN is administered concomitantly with levodopa or carbidopa-levodopa combination products, the most common adverse reactions have included dyskinesias such as choreiform, dystonic, and other involuntary movements and nausea. Other adverse reactions reported with LODOSYN when administered concomitantly with levodopa alone or carbidopa-levodopa combination products were psychotic episodes including delusions, hallucinations, and paranoid ideation, depression with or without development of suicidal tendencies, and dementia. Convulsions also have occurred; however, a causal relationship with concomitant use of LODOSYN and levodopa has not been established.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Satori Pharmaceuticals Adds Key Senior Members to its Leadership Team
2. MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit
3. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
4. Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
5. Colorcon Acquires Pharmaceutical Excipient Company - NP Pharm
6. pHase Pharmaceuticals Announces New Venture
7. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
8. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
9. Biostar Pharmaceuticals Approved for Listing on NASDAQ Global Market
10. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
11. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... capillary electrophoresis market to grow at a CAGR of 7.06% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:3/23/2017)... 23, 2017  Drug diversion is a significant ... deadly overdoses. A new oral fluid monitoring test, ... , reports more detailed and actionable information to ... improve therapy adherence, patient safety, and help to ... Oral fluid Rx Evaluation (CORE) system is the ...
(Date:3/23/2017)... SAN DIEGO , March 23, 2017 /PRNewswire/ ... for fast and accurate identification of individuals who ... at risk for a rare yet potentially deadly ... seizures and bipolar disorder.  The gene HLA-B*15:02 ... hypersensitivity reactions such as Stevens-Johnson syndrome and toxic ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National ... preparation programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT ... teacher quality in the U.S. It argues that this higher bar should be set ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of ... industry or whose acts have had a significant impact on the careers of all others ... Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. The induction ...
(Date:3/23/2017)... ... 23, 2017 , ... March is National Kidney Month – the perfect time ... to maintaining good health. Every day, two kidneys filter about 120 to 150 quarts ... your blood, eliminating waste, regulating fluid levels and blood pressure, supporting bone health and ...
(Date:3/23/2017)... ... March 23, 2017 , ... Hakim Unique Group (HUG) ... company California Healthcom Group (CHG). , The HUG investment is a landmark ... in California, CHG is a growing, internationally recognized healthcare management, technology, and services ...
Breaking Medicine News(10 mins):